Abstract 103P
Background
Liquid biopsy is a promising, noninvasive approach for early cancer detection. However, the extremely low portion of circulating tumor DNA (ctDNA) shedding into the blood in early lung cancer limits the screening application. Exploring the multi-layer epigenetic alterations accompanied with carcinogenesis could enhance the detection capacity of liquid biopsies. Therefore, we leveraged this cross-information to represent transcriptional and pathological characteristics of lung cancer and developed an accurate and sensitive model for early-stage lung cancer screening.
Methods
Participants with lung cancer (n=211), especially early-stage lung cancer (stage 0-I, n=145), benign nodules (n=33), and healthy volunteers (n=132) were recruited from two independent clinical centers (training center n=191, external validation center n=185). Peripheral blood cfDNA samples were simultaneously subjected to ChIP-seq, RRBS, and low-pass WGS (lpWGS). Cancer-specific synergistic effect among cell-free nucleosome H3K4me3, cfDNA methylation, and cfDNA nucleosomal deleted regions (NDRs) were analyzed to filter out Multi-Epigenetic Regulated GEnes (MERGE). A stacked ensemble machine learning model based on lpWGS was developed by integrating fragmentomic features centering around MERGE.
Results
A total of 655 MERGE were identified from a set of training cohort. Functional annotation revealed their association with transcription factors related to early lung cancer, including KLF15, SP1, and E2F families. The cfDNA fragment motifs displayed more distinct cancer-specific patterns in MERGE regions than in whole-genome. The MERGE-based integrated model was validated in an external cohort (81.7% at 0-I stage), achieving a sensitivity of 90.4% at specificity of 83.1% (AUC, 0.94), and demonstrated its high sensitivity of 93.1% at IA stage, 95.2% of minimally invasive adenocarcinoma (MIA) and 78.3% of adenocarcinoma in situ (AIS).
Conclusions
We developed a novel method by effectively enriching biologically meaningful epigenetic regulated regions, and established an integrated model for enhanced early detection of lung cancer during curable phases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Weihe Medical Laboratory Co. Ltd.
Funding
Shanghai Weihe Medical Laboratory Co. ltd Shanghai Weihe Medical Laboratory Co. Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08
112P - Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop
Presenter: Vincent de Jager
Session: Poster session 08